Acuity Pharmaceuticals is developing siRNA therapeutics for the treatment of age-related macular degeneration.

History:

In mid-2007 Acuity Pharmaceuticals and Froptix went through a reverse merger with eXegenics to become Opko.

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Other US

Research Focus:
RNAi Disease Therapeutics-Research Therapeutics-Development Therapeutics-Clinical early (I, II)

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: